You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Approach to Purifying iPSC Derived Cell Cultures

    SBC: HocusLocus Inc.            Topic: 200

    DESCRIPTION provided by applicant We are pioneering an RNA based switch technology called structurally interacting RNAs sxRNA which utilizes post transcriptional gene regulation as a reporter for miRNA detection Normally RNA binding proteins RBP associate with a andapos stem loop structure to facilitate translation of an upstream coding region by as much as an order of magnitude It is ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Automated Assessment of Leptomeningeal Collaterals on CT Angiograms

    SBC: KITWARE INC            Topic: 108

    DESCRIPTION provided by applicant The primary goal of this study is to develop an automated scoring system of leptomeningeal collaterals based on CT angiography CTA as a quantitative assessment of acute stroke Leptomeningeal collaterals provide an alternate path of blood flow in the setting of a proximal occlusion The presence and effectiveness of leptomeningeal collaterals i e andquot c ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Axonal Transport HTS Platform for Neurodegeneration Drug Discovery

    SBC: Bellbrook Labs, LLC            Topic: 106

    DESCRIPTION provided by applicant Neurodegenerative diseases that affect motor neurons such as PD ALS and HD represent an enormous unmet medical need that is growing with the aging population Existing treatments have little or no effect on the course of disease and patients have to cope with the loss of brain and body function for the rest of their lives Defects in the transport of organell ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Biological treatment of bacterial keratitis

    SBC: AMEBAGONE INC            Topic: N

    DESCRIPTION provided by applicant Staphylococcus is the most common cause of infections worldwide The pathogen persists asymptomatically on human skin from which it may spread to ocular tissues and cause corneal infection When this happens corneal bacterial keratitis can occur and if not treated effectively it may lead to blindness Multi Drug Resistant MDR variants of S aureus Sa are ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a high-throughput assay for measuring m6A demethylase activity

    SBC: Base5 Biosciences Inc            Topic: NIDA

    DESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Antigen Capture Assay for Babesia microti

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    DESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    DESCRIPTION provided by applicant Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a propri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government